Brazil faces a boom in the black market for weight-loss drugs amid GLP-1 demand
The high cost of GLP-1 treatments and prescription restrictions are driving illegal sales in Brazil of tirzepatide from Paraguay and unregulated compounded preparations. Itaú BBA estimates off-pharmacy sales will reach nearly 19 billion reais this year, of which about 6.5 billion would come from Paraguayan products diverted into the country. Anvisa and the Federal Police are investigating the health risks, while pharmacy robberies targeting these drugs worry authorities.


















